Peregrine Pharmaceuticals and Affitech will collaborate on the production of human antibodies for Peregrine's vascular targeting agent and anti-angiogenesis programs. Tustin, CA-based Peregrine will provide targets, while Affitech of Oslo, Norway, will apply its human antibody libraries and discovery and screening technologies to generate a panel of human antibodies against the targets. The firms did not release financial details of the relationship.
By AuntMinnie.com staff writersJune 18, 2003
Related Reading
Peregrine regains Nasdaq compliance, June 12, 2003
Peregrine, Schering team up, January 7, 2003
Peregrine begins Nasdaq grace period, August 22, 2002
Peregrine closes institutional investment deal, August 14, 2002
Peregrine lands $5.75 million investment, November 19, 2001
Copyright © 2003 AuntMinnie.com